1572-98-1

Usage

Uses

Used in Pharmaceutical Industry:
2-CYANO-2-METHYLPROPIONIC ACID ETHYL ESTER is used as an intermediate for the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the development of new drugs and medications, contributing to the advancement of medical treatments.
Used in Organic Synthesis:
In the field of organic chemistry, 2-CYANO-2-METHYLPROPIONIC ACID ETHYL ESTER serves as an important intermediate for the synthesis of a wide range of organic compounds. Its versatility in chemical reactions enables the creation of diverse molecules with specific properties and applications, further expanding the scope of organic synthesis.
Chemical Properties:
As a colorless liquid, 2-CYANO-2-METHYLPROPIONIC ACID ETHYL ESTER exhibits specific chemical properties that make it a valuable compound in various applications. Its cyano and ester groups provide unique reactivity and functional group interactions, which are essential for its use in pharmaceutical and organic synthesis.

InChI:InChI=1/C7H11NO2/c1-4-10-6(9)7(2,3)5-8/h4H2,1-3H3

Upstream product

• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 
• 1572-99-2 ethyl 2-cyanopropionate 
• 74-88-4 methyl iodide 
• 18852-51-2 sodium cyanoacetic acid ethyl ester 
• 77-78-1 dimethyl sulfate 
• 105-56-6 ethyl 2-cyanoacetate 
• 75-93-4 methyl bisulfate 
• 74-87-3 methylene chloride 
• 109539-54-0 ethyl 3-bromo-2-cyano-2-methylpropanoate 
• 600-00-0 ethyl 2-bromoisobutyrate 
• 13435-20-6 tetraethylammoniumcyanide 

Downstream Products

• 22426-30-8 2-cyano-2-methylpropanoic acid 
• 59193-77-0 3-amino-2,2-dimethylpropionic acid ethyl ester 
• 180181-02-6 3-(tert-Butoxycarbonyl)amino-2,2-dimethylpropanoic Acid 
• 204514-14-7 ethyl 2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate 
• 19295-57-9 3-hydroxy-2,2-dimethylpropionitrile 
• 1073723-10-0 ethyl 1-benzyl-5,5-dimethyl-4-oxopiperidine-3-carboxylate 
• 1332455-38-5 C₁₉H₂₉NO₄ 
• 173338-07-3 tert-butyl (3S,5S,6S,8S)-8-(3-amino-2,2-dimethyl-3-oxopropylcarbamoyl)-6-hydroxy-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-2,9-dimethyldecan-5-ylcarbamate 
• 1455092-35-9 ethyl 3-(7-(2-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carboxamido)-2,2-dimethylpropanoate 
• 1455087-69-0 3-(7-(2-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carboxamido)-2,2-dimethylpropanoic acid 
• 1455092-38-2 3-{[7-(3-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid ethyl ester 
• 1455087-70-3 3-{[7-(3-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid 
• 1455092-43-9 3-{[7-(4-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid ethyl ester 
• 1455087-73-6 3-{[7-(4-chlorophenoxy)-1-cyano-4-hydroxyisoquinoline-3-carbonyl]amino}-2,2-dimethylpropionic acid 

Relevant academic research and scientific papers

The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic

The Asp-Pro sequence of the cyclic peptide Ac-HN-Tyr-Cys*-Asp-Pro-Cys*-OH (1) could be replaced with the achiral dipeptide mimetic 1-(2-aminoethyl)cyclpentylcarboxylic acid with retention of potent inhibition of the VCAM-VLA-4 interaction. (C) Elsevier Science Ltd. All rights reserved.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compound and composition thereof, and uses of substituted heteroaryl compound and composition thereof

The present invention provides a substituted heteroaryl compound and a composition thereof, and uses of the substituted heteroaryl compound and the composition, wherein the compound is a compound represented by a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by the formula (I). The present invention further provides a pharmaceutical composition containing the compound, wherein the pharmaceutical composition can regulate activity of protein kinases, particularly Aurora kinases and JAK kinases, and can be used for prevention, treatment, therapy and alleviation of protein kinases, particularly Aurora kinases and JAK kinase activity mediated diseases or disorders.

Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis

A previous publication from this lab (Patrick, et al. Bioorg. Med. Chem. 2016, 24, 2451-2465) explored the antitrypanosomal activities of novel derivatives of 2-(2-benzamido)ethyl-4-phenylthiazole (1), which had been identified as a hit against Trypanosoma brucei, the causative agent of human African trypanosomiasis. While a number of these compounds, particularly the urea analogues, were quite potent, these molecules as a whole exhibited poor metabolic stability. The present work describes the synthesis of 65 new analogues arising from medicinal chemistry optimization at different sites on the molecule. The most promising compounds were the urea derivatives of 2-aryl-benzothiazol-5-amines. One such analogue, (S)-2-(3,4-difluorophenyl)-5-(3-fluoro-N-pyrrolidylamido)benzothiazole (57) was chosen for in vivo efficacy studies based upon in vitro activity, metabolic stability, and brain penetration. This compound attained 5/5 cures in murine models of both early and late stage human African trypanosomiasis, representing a new lead for the development of drugs to combat this neglected disease.

A new synthesis of bicyclic N,O- and N,S-enaminals by the anionic cyclization of alk-4-ynals with amino alcohols and amino thiols

A reaction of alk-4-ynals with aliphatic amino alcohols or 2-aminoethanethiol in the system DMSO - KOH gives bicyclic N,O- and N,S-enaminals: 6-methylidenehexahydro-2H-pyrrolo[2,1-b][1,3]oxazines, 5-methylidenehexahydropyrrolo[2,1-b]oxazoles, or 5-methyl-

Synthesis of oxazolidin-2-ones and imidazolidin-2-ones directly from 1,3-diols or 3-amino alcohols using iodobenzene dichloride and sodium azide

A general and efficient method for the synthesis of oxazolidin-2-ones and imidazolidin-2-ones directly from 1,3-diols and 3-amino alcohols has been developed using the same reagent combination of iodobenzene dichloride (PhICl2) and sodium azide (NaN3).

USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS

The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

Rhodium-catalyzed asymmetric hydrogenation of olefins with PhthalaPhos, a new class of chiral supramolecular ligands

A library of 19 binol-derived chiral monophosphites that contain a phthalic acid diamide group (Phthala- Phos) has been designed and synthesized in four steps. These new ligands were screened in the rhodium-catalyzed enantioselective hydrogenation of prochiral dehydroamino esters and enamides. Several members of the library showed excellent enantioselectivity with methyl 2-acetamido acrylate (6 ligands gave >97% ee), methyl (Z)-2- acetamido cinnamate (6 ligands gave >94% ee), and N-(1-phenylvinyl)acetamide (9 ligands gave >95% ee), whilst only a few representatives afforded high enantioselectivities for challenging and industrially relevant substrates N-(3,4-dihydronaphthalen-1- yl)-acetamide (96% ee in one case) and methyl (E)-2-(acetamidomethyl)-3- phenylacrylate (99% ee in one case). In most cases, the new ligands were more active and more stereoselective than their structurally related monodentate phosphites (which are devoid of functional groups that are capable of hydrogen-bonding interactions). Control experiments and kinetic studies were carried out that allowed us to demonstrate that hydrogen-bonding interactions involving the diamide group of the PhthalaPhos ligands strongly contribute to their outstanding catalytic properties. Computational studies carried out on a rhodium precatalyst and on a conceivable intermediate in the hydrogenation catalytic cycle shed some light on the role played by hydrogen bonding, which is likely to act in a substrate-orientation effect.

β-aryl nitrile construction via palladium-catalyzed decarboxylative benzylation of α-cyano aliphatic carboxylate salts

The palladium-catalyzed decarboxylative benzylation of α-cyano aliphatic carboxylate salts with benzyl electrophiles was discovered. This reaction exhibits good functional group compatibility and proceeds under relatively mild conditions. A diverse range of quaternary, tertiary and secondary β-aryl nitriles can be conveniently prepared by this method. Copyright

PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES

The present application relates to a process for the preparation of aliskiren and its pharmaceutically acceptable salts. In particular, the present application relates to a process for the preparation of intermediates for aliskiren, and their conversion to aliskiren or its salts.